Fig. 2From: Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenibProgression-free survival of patients with, compared to patients without, objective response. CI, confidence interval; PFS, progression-free survivalBack to article page